Top in hem/onc: Tax loss harvesting, myelodysplastic syndrome care

In their most recent column, Sanjeev Bhatia, MD, and David B. Mandell, JD, MBA, explain tax loss harvesting and how it can be an effective strategy for reducing tax obligations. It was the top story in hematology/oncology last week.

Another top story covered a presentation by David A. Sallman, MD, regarding the incorporation of next-generation sequencing into treatment for patients with myelodysplastic syndrome.

Read these and more top stories in hematology/oncology below:

Tax loss harvesting is a powerful tax strategy that should be implemented year-round

As we approach year end, many physicians inquire about ways to reduce their tax obligations for the current tax year. Read more.

Next-generation sequencing to impact all aspects of care for myelodysplastic syndrome

Incorporation of next-generation sequencing into standard of practice will be required for patients with myelodysplastic syndrome and will impact all facets of care, according to a speaker at Chemotherapy Foundation Symposium. Read more.

Blood donor characteristics linked to outcomes of very low-birth-weight infants

Very low-birth-weight infants who received blood transfusions from female donors had a lower risk for mortality and/or serious morbidity than those who received transfusions from male donors, study results showed. Read more.

Female hem/oncs seek to raise awareness of physician infertility

Long work hours, demanding training during reproductive years and overall stress may lead some physicians to delay their plans to start a family. Read more.

CAR T-cell therapy linked to cardiovascular, pulmonary adverse effects

Chimeric antigen receptor T-cell therapy appeared associated with various cardiovascular and pulmonary adverse events, according to results of a retrospective pharmacovigilance study. Read more.